425 related articles for article (PubMed ID: 10688973)
1. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors.
Hawkinson JE; Acosta-Burruel M; Espitia SA
Eur J Pharmacol; 2000 Feb; 389(2-3):107-14. PubMed ID: 10688973
[TBL] [Abstract][Full Text] [Related]
2. In vitro inhibitory effects of J-113397 on nociceptin/orphanin FQ-stimulated.
Ichikawa D; Ozaki S; Azuma T; Nambu H; Kawamoto H; Iwasawa Y; Takeshima H; Ohta H
Neuroreport; 2001 Jun; 12(8):1757-61. PubMed ID: 11409754
[TBL] [Abstract][Full Text] [Related]
3. Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.
Sim LJ; Childers SR
J Comp Neurol; 1997 Oct; 386(4):562-72. PubMed ID: 9378852
[TBL] [Abstract][Full Text] [Related]
4. Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors.
Neal CR; Owens CE; Taylor LP; Hoversten MT; Akil H; Watson SJ
J Chem Neuroanat; 2003 Jul; 25(4):233-47. PubMed ID: 12842269
[TBL] [Abstract][Full Text] [Related]
5. Identification of the G-protein-coupled ORL1 receptor in the mouse spinal cord by [35S]-GTPgammaS binding and immunohistochemistry.
Narita M; Mizoguchi H; Oji DE; Dun NJ; Hwang BH; Nagase H; Tseng LF
Br J Pharmacol; 1999 Nov; 128(6):1300-6. PubMed ID: 10578145
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.
Ozaki S; Kawamoto H; Itoh Y; Miyaji M; Azuma T; Ichikawa D; Nambu H; Iguchi T; Iwasawa Y; Ohta H
Eur J Pharmacol; 2000 Aug; 402(1-2):45-53. PubMed ID: 10940356
[TBL] [Abstract][Full Text] [Related]
7. Nociceptin activation of the human ORL1 receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors.
Fawzi AB; Zhang H; Weig B; Hawes B; Graziano MP
Eur J Pharmacol; 1997 Oct; 336(2-3):233-42. PubMed ID: 9384238
[TBL] [Abstract][Full Text] [Related]
8. Nociceptin (orphanin FQ): high-affinity and high-capacity binding site coupled to low-potency stimulation of guanylyl-5'-O-(gamma-thio)-triphosphate binding in rat brain membranes.
Albrecht E; Samovilova NN; Oswald S; Baeger I; Berger H
J Pharmacol Exp Ther; 1998 Aug; 286(2):896-902. PubMed ID: 9694948
[TBL] [Abstract][Full Text] [Related]
9. G protein activation and cyclic AMP modulation by naloxone benzoylhydrazone in distinct layers of rat olfactory bulb.
Onali P; Olianas MC
Br J Pharmacol; 2004 Nov; 143(5):638-48. PubMed ID: 15451772
[TBL] [Abstract][Full Text] [Related]
10. Replacement of Gln280 by His in TM6 of the human ORL1 receptor increases affinity but reduces intrinsic activity of opioids.
Mollereau C; Moisand C; Butour JL; Parmentier M; Meunier JC
FEBS Lett; 1996 Oct; 395(1):17-21. PubMed ID: 8849681
[TBL] [Abstract][Full Text] [Related]
11. [Nphe(1)]NC(1-13)NH(2) selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain.
Berger H; Calo' G; Albrecht E; Guerrini R; Bienert M
J Pharmacol Exp Ther; 2000 Aug; 294(2):428-33. PubMed ID: 10900215
[TBL] [Abstract][Full Text] [Related]
12. Distribution of nociceptin and Ro64-6198 activated [35S]-GTPgammaS binding in the rat brain.
Gehlert DR; Gackenheimer SL; Shaw JL
Neuropeptides; 2006 Apr; 40(2):95-105. PubMed ID: 16403422
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
14. Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids.
Butour JL; Moisand C; Mazarguil H; Mollereau C; Meunier JC
Eur J Pharmacol; 1997 Feb; 321(1):97-103. PubMed ID: 9083791
[TBL] [Abstract][Full Text] [Related]
15. Opioid receptor-like 1 (NOP) receptors in the rat dorsal raphe nucleus: evidence for localization on serotoninergic neurons and functional adaptation after 5,7-dihydroxytryptamine lesion.
Le Maître E; Vilpoux C; Costentin J; Leroux-Nicollet I
J Neurosci Res; 2005 Aug; 81(4):488-96. PubMed ID: 15948180
[TBL] [Abstract][Full Text] [Related]
16. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.
Bloms-Funke P; Gillen C; Schuettler AJ; Wnendt S
Peptides; 2000 Jul; 21(7):1141-6. PubMed ID: 10998549
[TBL] [Abstract][Full Text] [Related]
17. [Phe1phi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 acts as a partial agonist at ORL1 receptor endogenously expressed in mouse N1E-115 neuroblastoma cells.
Olianas MC; Maullu C; Ingianni A; Onali P
Neuroreport; 1999 Apr; 10(5):1127-31. PubMed ID: 10321496
[TBL] [Abstract][Full Text] [Related]
18. In vitro pharmacological profile of peptide III-BTD: a novel ligand for nociceptin/orphanin FQ and opioid receptors.
Bigoni R; Rizzi A; Rizzi D; Becker JA; Kieffer BL; Simonin F; Regoli D; Calo G
Life Sci; 2000 Dec; 68(2):233-9. PubMed ID: 11191640
[TBL] [Abstract][Full Text] [Related]
19. Differential antagonism by naloxone benzoylhydrazone of the activation of inward rectifying K+ channels by nociceptin and a mu-opioid in rat periaqueductal grey slices.
Chiou LC
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jun; 363(6):583-9. PubMed ID: 11414652
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological studies on the "orphan" opioid receptor in central and peripheral sites.
Nicholson JR; Paterson SJ; Menzies JR; Corbett AD; McKnight AT
Can J Physiol Pharmacol; 1998 Mar; 76(3):304-13. PubMed ID: 9673794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
